Biological determinants of the intestinotrophic properties of glp-2
in vivo.
Tsai, Chun-Hui, Mary Hill, and Daniel J. Drucker.
Department of Medicine, The Toronto Hospital, Banting and Best
Diabetes Centre, University of Toronto, Toronto, Ontario M5G2C4
APStracts 3:0235G, 1996.
GLP-2 appears to regulate growth of the small bowel epithelium. The
importance of dose, vehicle, and route of administration for GLP-2
bioactivity was examined in vivo. Mouse small bowel weight increased
following s.c injection of GLP-2, 0.25 to 5.0 ug twice daily, with an
increment in jejunal crypt plus villus height detected with only 250
ng GLP-2 b.i.d for 14 days (1.35-fold greater than control,
p<.05). Small bowel weight was increased by 6 days of GLP-2
administration (1.4-fold greater than control, p<.05), and
further increased after up to14 days of GLP-2 treatment
(p<.001, GLP-2 vs control). GLP-2 increased small bowel weight
in either 12% gelatin or PBS formulations (p<.01 vs
p<.05, gelatin vs PBS, respectively) and GLP-2 was
intestinotrophic following either IM, IP, or SC administration
(p<.05 for IM and IP, p<.001 for SC, GLP-2 vs control).
GLP-2 also induced bowel growth when administered daily or every
other day. These results define important biological parameters for
the activity of GLP-2 in vivo.
Received 5 August 1996; accepted in final form 17 October 1996.
APS Manuscript Number G319-6.
Article publication pending Am. J. Physiol. (Gastrointest. Liver
Physiology).
ISSN 1080-4757 Copyright 1996 The American Physiological Society.
Published in APStracts on 13 November 1996